Miller K - Search Results

1

Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.

Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, Burris HA 3rd, Albain KS, Harbeck N, Dieras V, Crivellari D, Fang L, Guardino E, Olsen SR, Crocker LM, Sliwkowski MX. Phillips GD, et al. Among authors: miller k. Clin Cancer Res. 2014 Jan 15;20(2):456-68. doi: 10.1158/1078-0432.CCR-13-0358. Epub 2013 Oct 4. Clin Cancer Res. 2014. PMID: 24097864 Clinical Trial.

2

Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.

Miller KD, Sisk J, Ansari R, Gize G, Nattam S, Pennington K, Monaco F, Sledge GW Jr. Miller KD, et al. Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):38-40. Oncology (Williston Park). 2001. PMID: 11252888 Clinical Trial.

3

The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.

Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr. Sweeney CJ, et al. Among authors: miller kd. Cancer Res. 2001 Apr 15;61(8):3369-72. Cancer Res. 2001. PMID: 11309294

4

EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.

Lu M, Miller KD, Gokmen-Polar Y, Jeng MH, Kinch MS. Lu M, et al. Cancer Res. 2003 Jun 15;63(12):3425-9. Cancer Res. 2003. PMID: 12810680

5

A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer.

Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, Sparano JA, Wolff AC, Cobleigh MA, Galbraith S, Sledge GW. Miller KD, et al. Clin Cancer Res. 2004 Mar 15;10(6):1971-5. doi: 10.1158/1078-0432.ccr-03-0968. Clin Cancer Res. 2004. PMID: 15041714 Clinical Trial.

6

The role of ErbB inhibitors in trastuzumab resistance.

Miller KD. Miller KD. Oncologist. 2004;9 Suppl 3:16-9. doi: 10.1634/theoncologist.9-suppl_3-16. Oncologist. 2004. PMID: 15163843 Free article. Review.

7

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.

Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, Baselga J. Miller KD, et al. Clin Cancer Res. 2005 May 1;11(9):3369-76. doi: 10.1158/1078-0432.CCR-04-1923. Clin Cancer Res. 2005. PMID: 15867237 Clinical Trial.

8

A physiologic imaging pilot study of breast cancer treated with AZD2171.

Miller KD, Miller M, Mehrotra S, Agarwal B, Mock BH, Zheng QH, Badve S, Hutchins GD, Sledge GW Jr. Miller KD, et al. Clin Cancer Res. 2006 Jan 1;12(1):281-8. doi: 10.1158/1078-0432.CCR-05-0219. Clin Cancer Res. 2006. PMID: 16397053

9

Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.

Hochreiter AE, Xiao H, Goldblatt EM, Gryaznov SM, Miller KD, Badve S, Sledge GW, Herbert BS. Hochreiter AE, et al. Clin Cancer Res. 2006 May 15;12(10):3184-92. doi: 10.1158/1078-0432.CCR-05-2760. Clin Cancer Res. 2006. PMID: 16707619

10

Development of new targeted therapies for breast cancer.

Doyle DM, Miller KD. Doyle DM, et al. Cancer Treat Res. 2008;141:119-34. doi: 10.1007/978-0-387-73161-2_8. Cancer Treat Res. 2008. PMID: 18274086 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,807 results

Search Page

Filters